499 Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder.
http://www.nature.com/ncomms/2013/131119/ncomms3739/full/ncomms3739.html
498 Deletions of chromosome 22q13.3 cause Phelan–McDermid syndrome (PMDS), a neurodevelopmental disorder associated with autism; here induced pluripotent stem cells from PMDS patients with autism are used to produce neurons, they are shown to have reduced SHANK3 expression and a defect in excitatory synaptic transmission which can be restored either by increasing SHANK3 or with insulin-like growth factor 1.
http://www.nature.com/nature/journal/v503/n7475/full/nature12618.html
497 High-speed laser microsurgery of alert fruit flies for fluorescence imaging of neural activity.
http://www.pnas.org/content/110/46/18374.abstract
496 Human genome–guided identification of memory-modulating drugs.
http://www.pnas.org/content/110/46/E4369.abstract
495 Chondroitin sulphate N-acetylgalactosaminyl-transferase-1 inhibits recovery from neural injury.
http://www.nature.com/ncomms/2013/131112/ncomms3740/full/ncomms3740.html
494 A cholinergic trigger drives learning-induced plasticity at hippocampal synapses.
http://www.nature.com/ncomms/2013/131112/ncomms3760/full/ncomms3760.html
493 Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress.
http://www.nature.com/ncomms/2013/131112/ncomms3753/full/ncomms3753.html
492 Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid .
http://www.nature.com/neuro/journal/v16/n11/abs/nn.3540.html
491 There is currently no effective treatment for infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disease that occurs in childhood. Here the authors show that a small molecule thioesterase-mimetic can alleviate neuropathology and extend lifespan in an animal model of the disease.
http://www.nature.com/neuro/journal/v16/n11/abs/nn.3526.html
490 Dysfunction of the potassium-chloride cotransporter KCC2 has been linked to many neurological diseases, including pain, anxiety and epilepsy. Now, Yves De Koninck and his colleagues report that they have developed a novel small-molecule compound that is orally bioavailable and can activate KCC2 and reduce chronic pain in rats.
http://www.nature.com/nm/journal/v19/n11/abs/nm.3356.html
|
